A review of the cytokine network in multiple myeloma: Diagnostic, prognostic, and therapeutic implications

Cancer

Volumn 97, Issue 10, 2003, Pages 2440-2452

  Lauta, Vito Michele ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Cytokines; Interleukin 6 (IL 6); Multiple myeloma; Response

Indexed keywords

ANTIIDIOTYPIC VACCINE; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CANCER VACCINE; CELL ADHESION MOLECULE; CYTOKINE; DEXAMETHASONE; DOXORUBICIN; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MELPHALAN; MONOCLONAL ANTIBODY; PREDNISONE; RECOMBINANT ALPHA2 INTERFERON; UNCLASSIFIED DRUG; VINCRISTINE;

AUTOCRINE EFFECT; BLOOD; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; EVALUATION; HORMONAL THERAPY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MONONUCLEAR CELL; MULTIPLE MYELOMA; NONHUMAN; PARACRINE SIGNALING; PARAMETER; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; STROMA CELL; TARGET CELL; THROMBOCYTOPENIA; TREATMENT FAILURE; IMMUNOLOGY; IMMUNOTHERAPY; MORTALITY; PATHOLOGY; SURVIVAL;

CYTOKINES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-6; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0038370952     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11072     Document Type: Review

References (41)

1. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am. 1992;6:273-284.
2. Teoh G, Anderson KC. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am. 1997;11:27-42.
3. Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma cell growth factor in patients with aggressive multiple myeloma. Blood. 1989;74:111-113.
4. Klein B, Wudenes J, Zhang XG. Murine anti-interleukin-6 monoclonal antibody therapy in a patient with plasma cell leukemia. Blood. 1991;78:1198-1204.
5. Urashima M, Ogata A, Chauhan D, et al. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. Blood. 1996;88:2219-2227.
6. Nachbaur DM, Herold M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol. 1991;62: 54-58.
7. Donovan KA, Lacy MQ, Kline MP, et al. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Leukemia. 1998;12:593-600.
8. Gernone A, Dammacco F. Molecular alterations of IL-6R, IcK and c-myc genes in transforming monoclonal gammopathy of undetermined significance. Br J Haematol. 1996; 93:623-631.
9. Emile C, Fermand JP, Danon F. Interleukin-6 serum levels in patients with multiple myeloma. Br J Haematol. 1994;86: 439-440.
10. Vacca A, Di Stefano R, Frassanito A, Iodice G, Dammacco F. A disturbance of the IL-2/IL-2 receptor systems parallels the activity of multiple myeloma. Clin Exp Immunol. 1991;84: 429-434.
11. Sawamura M, Murakami H, Tsuchiya J. Tumor necrosis factor-α and interleukin-4 in myeloma cell precursor differentiation. Leuk Lymphoma. 1996;21:31-36.
12. Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer. 1998;82:1860-1866.
13. Treon SP, Anderson KC. Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Curr Opin Haematol. 1998;5:42-48.
14. Papadaki H, Kyriakov D, Foudoulakis A, Markidov F, Alexandrakis M, Eliopoulos G. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol. 1997;97:191-195.
15. Kyrtsonis MC, Dedoussis G, Zervas C, et al. Soluble interleukin-6 receptor (slL-6R), a new prognostic factor in multiple myeloma. Br J Haematol. 1996;93:398-400.
16. Van Zaanen HCT, Lokhorst HM, Aarden LA, et al. Chimaeric anti-interleukin-6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol. 1998;102:783-790.
17. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R. A combination of anti-interleukin-6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol. 2000;109:661-664.
18. Sporano E, Savino R, Ciapponi L, et al. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood. 1996;87:4510-4519.
19. Bergenbrandt S, Yi Q, Österborg A, et al. Modulation of anti-idiotypic immune response by immunization with autologous M-component protein in multiple myeloma patients. Br J Haematol. 1996;92:840-846.
20. Kwak LW, Thielemans K, Massaia M. Idiotypic vaccination as therapy for multiple myeloma. Semin Oncol. 1999;36:34-37.
21. Reichardt VL, Okada CY, Stockeri-Goldstein KE, Bogen B, Levy R. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant. 1997;3:157-163.
22. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood. 1999;94:673-683.
23. Stevenson FK, Anderson KC. Preparing the ground for vaccination against multiple myeloma. Immunol Today. 2000; 21:170-171.
24. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer. 1999;83: 215-222.
25. Cull G, Durrant L, Stainer C, Haynes A, Russel N. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999;107:648-655.
26. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol. 2000;108:805-816.
27. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma. A feasibility study. Blood. 1999;93:2411-2419.
28. Österborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type-I, major histocompatibility complex-restricted, CD8- and CD4-specific specific T-cell responses. Blood. 1998;91:2459-2466.
29. Lauta VM. The use of interferon in the treatment of hematologic malignancies. Inflamacion. 1995;6:78-87.
30. Liu P, Oken M, Van Ness B. Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis. Leukemia. 1999;13:473-480.
31. Lauta VM. Interferon and multiple myeloma. Med Oncol. 1995;12:63-69.
32. Mandelli F, Avvisati G, Amadori S, et al. Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med. 1990;322:1430-1434.
33. Westin J, Rodjer S, Turesson I, Cortelezi A, Hjorth M, Zador G. Interferon alpha 2b vs no maintenance therapy during the plateau-phase in multiple myeloma. Br J Haematol. 1995;89:561-568.
34. Kars A, Celik I, Konsu E, et al. Maintenance therapy with alpha interferon following first line VAD in multiple myeloma. Eur J Haematol. 1997;59:100-104.
35. Hubel K, Tesch H, Kroger B, et al. A phase I/II study of idarubicin, dexamethasone and interferon-α (I-Dexa) in patients with relapsed or refractory multiple myeloma. Leukemia. 1997;11(5):947-951.
36. Byrne JL, Carter GI, Bienz N, Haynes AP, Russel NH. Adjuvant alpha interferon improves complete remission rates following allogeneic transplantation for multiple myeloma. Bone Marrow Transplant. 1998;22:639-643.
37. Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol. 1998;102:495-502.
38. Bladé J, San Miguel JF, Escudero ML, et al. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program of the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Leukemia. 1998;12:1144-1148.
39. Salmon SE, Crowley JJ, Balcerzak P, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1998;16:890-896.
40. Offidani M, Olivieri A, Montillo M, et al. Two dosage interferon-a2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial. Haematologica. 1998;83:40-47.
41. Bjorkstrand B, Svensson H, Goldschmidt H, et al. Alphainterferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2001;27:511-515.